Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
C Kratochwil, WP Fendler, M Eiber, MS Hofman… - European journal of …, 2023 - Springer
Prostate-specific membrane antigen (PSMA) is expressed by the majority of clinically
significant prostate adenocarcinomas, and patients with target-positive disease can easily …
significant prostate adenocarcinomas, and patients with target-positive disease can easily …
177Lu‐PSMA radioligand therapy effectiveness in metastatic castration‐resistant prostate cancer: An updated systematic review and meta‐analysis
Background An updated systematic review and meta‐analysis of relevant studies to
evaluate the effectiveness of prostate‐specific membrane antigen (PSMA)‐targeted …
evaluate the effectiveness of prostate‐specific membrane antigen (PSMA)‐targeted …
[HTML][HTML] Pharmacological optimization of PSMA-based radioligand therapy
S van der Gaag, IH Bartelink, AN Vis, GL Burchell… - Biomedicines, 2022 - mdpi.com
Prostate cancer (PCa) is the most common malignancy in men of middle and older age. The
standard treatment strategy for PCa ranges from active surveillance in low-grade, localized …
standard treatment strategy for PCa ranges from active surveillance in low-grade, localized …
Spatiotemporal modeling of radiopharmaceutical transport in solid tumors: Application to 177Lu-PSMA therapy of prostate cancer
Background and objective 177 Lu-labeled prostate-specific membrane antigen (PSMA)
radiopharmaceutical therapy (RPT) represents a pivotal advancement in addressing …
radiopharmaceutical therapy (RPT) represents a pivotal advancement in addressing …
Prostate cancer lung metastasis: clinical insights and therapeutic strategies
Simple Summary In our paper, we examine various facets of prostate cancer lung
metastasis. We explore their clinical manifestations, such as respiratory symptoms and …
metastasis. We explore their clinical manifestations, such as respiratory symptoms and …
Peritoneal Metastases From Prostate Carcinoma Treated With 177Lu-PSMA-I&T
LW van Golen, TTP Seijkens, JM de Feijter… - Clinical Nuclear …, 2023 - journals.lww.com
A 71-year-old man was referred for 177 Lu-PSMA therapy. He had metastatic castration-
resistant prostate cancer, progressive on several treatment lines, with current PSA 260 μg/L …
resistant prostate cancer, progressive on several treatment lines, with current PSA 260 μg/L …
Efficacy and safety of therapies for advanced prostate cancer in Asia: Evidence from a systematic literature review
M Saad, R Umbas, E Chiong… - … Advances in Medical …, 2022 - journals.sagepub.com
Objectives: Several therapies are available for the treatment of advanced/metastatic prostate
cancer (PC). However, the systematic assessment of evidence pertaining to the use of these …
cancer (PC). However, the systematic assessment of evidence pertaining to the use of these …
Evaluation of Tumor Burden Response to Single-cycle of Lu-177 PSMA Treatment with Whole Body Scintigraphic Planar Images in Prostate Cancer Patients
EVALUATION OF TUMOR BURDEN RESPONSE TO SINGLE-CYCLE OF Lu-177 PSMA
TREATMENT WITH WHOLE BODY SCINTIGRAPHIC PLANAR IMAGES IN PROS Page 1 J …
TREATMENT WITH WHOLE BODY SCINTIGRAPHIC PLANAR IMAGES IN PROS Page 1 J …